EA033257B1 - Комбинация двух противовирусных препаратов для лечения гепатита c - Google Patents

Комбинация двух противовирусных препаратов для лечения гепатита c

Info

Publication number
EA033257B1
EA033257B1 EA201591702A EA201591702A EA033257B1 EA 033257 B1 EA033257 B1 EA 033257B1 EA 201591702 A EA201591702 A EA 201591702A EA 201591702 A EA201591702 A EA 201591702A EA 033257 B1 EA033257 B1 EA 033257B1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
antivirals
combination
treating hepatitis
ribavirin
Prior art date
Application number
EA201591702A
Other languages
English (en)
Other versions
EA201591702A1 (ru
Inventor
Барри М. Бернстейн
Сандип ДУТТА
Вэй ЛЮ
Томас Дж. Подсадеки
Эндрю Л. Кэмпбелл
Раджив М. Менон
Чих-Вэй Лин
Тяньли Ван
Валид М. Авни
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of EA201591702A1 publication Critical patent/EA201591702A1/ru
Publication of EA033257B1 publication Critical patent/EA033257B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к безинтерфероновым и безрибавириновым терапевтическим методам для лечения HCV. Предпочтительно, чтобы лечение имело меньшую продолжительность, например не более 12 недель. В одном аспекте лечение включает в себя введение по меньшей мере двух противовирусных препаратов прямого действия без интерферона и рибавирина субъекту с HCV-инфекцией, где лечение продолжается в течение 12 недель, и указанные по меньшей мере два противовирусных препарата прямого действия включают (а) соединение 1 или его фармацевтически приемлемую соль и (b) соединение 2 или его фармацевтически приемлемую соль.
EA201591702A 2013-03-14 2014-03-14 Комбинация двух противовирусных препаратов для лечения гепатита c EA033257B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783376P 2013-03-14 2013-03-14
PCT/US2014/027423 WO2014152514A1 (en) 2013-03-14 2014-03-14 Combination of two antivirals for treating hepatitis c

Publications (2)

Publication Number Publication Date
EA201591702A1 EA201591702A1 (ru) 2016-09-30
EA033257B1 true EA033257B1 (ru) 2019-09-30

Family

ID=50588882

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201991174A EA201991174A1 (ru) 2013-03-14 2014-03-14 Комбинация двух противовирусных препаратов для лечения гепатита c
EA201591702A EA033257B1 (ru) 2013-03-14 2014-03-14 Комбинация двух противовирусных препаратов для лечения гепатита c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201991174A EA201991174A1 (ru) 2013-03-14 2014-03-14 Комбинация двух противовирусных препаратов для лечения гепатита c

Country Status (26)

Country Link
US (1) US20140275099A1 (ru)
EP (3) EP2968301B1 (ru)
JP (4) JP6441303B2 (ru)
KR (2) KR102210935B1 (ru)
CN (2) CN108159393A (ru)
AU (2) AU2014239563B2 (ru)
BR (1) BR112015023017B1 (ru)
CA (1) CA2901810C (ru)
CY (2) CY1119025T1 (ru)
DK (2) DK2968301T3 (ru)
EA (2) EA201991174A1 (ru)
ES (2) ES2624980T3 (ru)
HK (2) HK1244668A1 (ru)
HR (2) HRP20171036T1 (ru)
HU (2) HUE052113T2 (ru)
IL (1) IL240419B (ru)
LT (2) LT2968301T (ru)
MX (2) MX362616B (ru)
NZ (2) NZ719137A (ru)
PL (2) PL3213750T3 (ru)
PT (2) PT2968301T (ru)
RS (2) RS56202B1 (ru)
SG (2) SG10201708306WA (ru)
SI (2) SI3213750T1 (ru)
TW (2) TWI686196B (ru)
WO (1) WO2014152514A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991174A1 (ru) 2013-03-14 2020-01-31 Эббви Инк. Комбинация двух противовирусных препаратов для лечения гепатита c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20160317603A9 (en) * 2013-03-14 2016-11-03 Abbvie Inc. Methods for Treating HCV
US20150011481A1 (en) * 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
JP2016534082A (ja) * 2013-10-25 2016-11-04 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
EP3082808A1 (en) * 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
JP6632992B2 (ja) * 2014-04-02 2020-01-22 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016283018C1 (en) * 2015-06-26 2022-03-03 Abbvie Inc. Solid pharmaceutical compositions for treating HCV
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
JP7133466B2 (ja) * 2015-07-17 2022-09-08 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための固体医薬組成物
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CA3037719A1 (en) * 2016-09-23 2018-03-29 Abbvie Inc. Dose adjustment
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
TW202012001A (zh) * 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
WO2020106835A1 (en) 2018-11-20 2020-05-28 Abbvie Inc. Methods for treating acute hcv
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물
CN111688355B (zh) 2019-03-15 2022-04-12 精工爱普生株式会社 液体吸收体、液体吸收器以及液体喷出装置
JP2020172484A (ja) * 2019-04-08 2020-10-22 アッヴィ・インコーポレイテッド Ｈｃｖを治療するための固体医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004196A1 (en) * 2009-06-11 2012-01-05 Abbott Labaoratories Anti-Viral Compounds
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014047039A1 (en) * 2012-09-18 2014-03-27 Abbvie Inc. Methods for treating hepatitis c

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8330139B2 (en) 2011-03-25 2012-12-11 Micron Technology, Inc. Multi-level memory cell
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
EA201991174A1 (ru) 2013-03-14 2020-01-31 Эббви Инк. Комбинация двух противовирусных препаратов для лечения гепатита c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004196A1 (en) * 2009-06-11 2012-01-05 Abbott Labaoratories Anti-Viral Compounds
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014047039A1 (en) * 2012-09-18 2014-03-27 Abbvie Inc. Methods for treating hepatitis c

Also Published As

Publication number Publication date
NZ719137A (en) 2017-11-24
CN105073113A (zh) 2015-11-18
EP3766495A1 (en) 2021-01-20
PL2968301T3 (pl) 2017-09-29
AU2016202823A1 (en) 2016-05-19
KR20150129032A (ko) 2015-11-18
EP2968301A1 (en) 2016-01-20
CA2901810A1 (en) 2014-09-25
MX2020005054A (es) 2020-08-20
WO2014152514A1 (en) 2014-09-25
TWI686196B (zh) 2020-03-01
SG11201507364SA (en) 2015-10-29
SI2968301T1 (sl) 2017-07-31
TW201834656A (zh) 2018-10-01
LT2968301T (lt) 2017-05-25
AU2014239563B2 (en) 2016-05-05
JP6441303B2 (ja) 2018-12-19
ES2824473T3 (es) 2021-05-12
HUE052113T2 (hu) 2021-04-28
HRP20201575T1 (hr) 2020-12-11
SG10201708306WA (en) 2017-11-29
KR102210935B1 (ko) 2021-02-02
RS56202B1 (sr) 2017-11-30
BR112015023017A2 (pt) 2017-07-18
CY1123387T1 (el) 2021-12-31
BR112015023017B1 (pt) 2022-08-30
MX362616B (es) 2019-01-28
US20140275099A1 (en) 2014-09-18
CN105073113B (zh) 2018-01-02
EP3213750A1 (en) 2017-09-06
RS60881B1 (sr) 2020-11-30
JP2019048868A (ja) 2019-03-28
EA201591702A1 (ru) 2016-09-30
TW201511759A (zh) 2015-04-01
PT2968301T (pt) 2017-07-17
SI3213750T1 (sl) 2020-11-30
ES2624980T3 (es) 2017-07-18
EP2968301B1 (en) 2017-04-19
JP6621902B2 (ja) 2019-12-18
DK2968301T3 (en) 2017-07-24
EA201991174A1 (ru) 2020-01-31
DK3213750T3 (da) 2020-10-19
JP2021130720A (ja) 2021-09-09
AU2016202823B2 (en) 2017-11-23
KR20210013344A (ko) 2021-02-03
IL240419B (en) 2019-03-31
CN108159393A (zh) 2018-06-15
CA2901810C (en) 2019-01-08
EP3213750B1 (en) 2020-08-12
JP2016513695A (ja) 2016-05-16
LT3213750T (lt) 2020-10-26
PL3213750T3 (pl) 2020-12-14
JP2020037589A (ja) 2020-03-12
MX2015012538A (es) 2016-02-10
HUE033010T2 (en) 2017-11-28
HRP20171036T1 (hr) 2017-10-06
HK1223817A1 (zh) 2017-08-11
PT3213750T (pt) 2020-10-19
AU2014239563A1 (en) 2015-08-27
CY1119025T1 (el) 2018-01-10
NZ631155A (en) 2016-05-27
IL240419A0 (en) 2015-09-24
HK1244668A1 (zh) 2018-08-17
TWI642436B (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
PH12020550065A1 (en) Hepatitis b antiviral agents
MX2018000240A (es) Metodos para tratar el vhc.
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
RU2015114566A (ru) Способы лечения гепатита с
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
TN2013000134A1 (en) Combination therapy for treating hcv infection